Nevertheless, as a novel interesting aspect, the study showed that decreased acetylation of H3K27, caused by KAT2B knockdown and knockout, brings about a low expression of BRCA2 in CRC cell lines, which would encourage the development of KAT2B as an additional therapeutic target in this scenario. The gene discussed is KAT2B; the disease is colorectal carcinoma.